CTOs on the Move

Cardiology Consultants of Philadelphia

www.ccpdocs.com

 
As America’s largest independent cardiac care practice, CCP is home to the most experienced cardiologists in the Philadelphia region.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.ccpdocs.com
  • 207, North Broad Street
    Philadelphia, PA USA 19107
  • Phone: 215.227.3627

Executives

Name Title Contact Details

Similar Companies

ISTA Pharmaceuticals

ISTA Pharmaceuticals, Inc. is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Merck

Today`s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside of the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.

JSJ Pharmaceuticals

JSJ Pharmaceuticals is a Charleston, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sol-Millennium Medical Group

SOL-MILLENNIUM is a vertically integrated global medical supply company with locations across the globe. We are one of the worlds largest manufacturers of needles, syringes, and blood collection devices with a comprehensive line of medical supplies fo...

Ascentage Pharma

Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology from the University of Michigan, the Company`s expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of six clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors.